[IR] Review of the Non-Deal Road Show held from June 7th to 8
PR
For a better future SCM Lifescience will do its best
[IR] Non-Deal Roadshow for institutional investors will be held from June 7th to 8
Notice
2022-11-15
SCM Lifescience, Inc. will hold a Non-Deal Road Show (NDR) for domestic institutional investors from June 7-8 to enhance their understanding of companies and enhance corporate value.
The meeting has been scheduled with a total of seven institutional investors with operating assets ranging from at least 593.7 billion won to up to 393.9 billion won and will hold corporate briefing sessions with various other institutional investors.
In this company briefing session, we will introduce the source technology of SCM Lifescience, which is differentiated from other bio companies. In addition, we will emphasize the importance of isolation and culture of high-purity stem cells that can only be realized with our original technology and will stimulate investment sentiment by explaining a sustainable business model based on the above.
This briefing session will be a good opportunity to confirm the future growth potential of SCM Lifescience, which is newly started, with the participation of Hyung-Nam Oh, Executive Vice President of IR/PR, and three headquarter managers. In addition, we will provide IR data that can meet the growing information needs of investors, thereby enhancing investor understanding and trust.
In the future, SCM Lifescience promises to actively secure investor trust by providing our sincere attitude and accurate information through holding a corporate briefing session involving all executives in charge.